Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Idarubicin combined with high dose methotrexate and moderate dose radiotherapy will achieve
similar survival outcomes but with reduced neurotoxicity compared to regimens using
methotrexate with high dose radiotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)